Craig Williams

Professor (Clinical)
Send an Email

Office: 503-494-1598

Credentials: 
Board Certified Pharmacotherapy Specialist, 2011
Fellow, National Lipid Association, 2009
Residency, Cedars-Sinai Medical Center, 1994–1995
Pharm.D., University of California at San Francisco, 1990–1994
Pre-Pharmacy, University of California at Los Angeles, 1987–1990

Profile Field Tabs

At OSU
Affiliated with: 
Pharmacy Professnl Instr
Faculty Type: 
Pharmacy Practice
Research/Career Interests: 

Ongoing Research Support

Medical School Grant, Merck Inc., 2002–present
Clinical trial of statins in patients with low HDL cholesterol

Completed Research Support

Kinetic study of enoxaparin dosing in chronic kidney disease
National Kidney Foundation; Hellman (PI)
2002–2005

Jointly funded by Clarian Health Centers, Pfizer and Sanofi-Aventis to establish city-wide lipid working group in effort to increase collaborative efforts on dyslipidemia in Indianapolis, Indiana
Multi-source Educational Center Grant
2003–2006

3-9% recurring annual salary support for clinical center working on several national, multi-center studies
Asthma Clinical Research Center Grant
2000–2006

Selected Publications

Book chapters:

  1. Williams C, Haffner S. Dyslipidemia in diabetes: epidemiology, complications, and management. In Therapy for Diabetes Mellitus and Related Disorders. 6th ed. Umpierrez GE, Ed. Alexandria, VA, American Diabetes Association, 2014, p. 908-920.
  2. Kroon L, Williams CD. Diabetes. In Koda-Kimble & Young’s Applied Therapeutics: The Clinical Use of Drugs, 10th Ed. Edited by Alldredge B, et al. 2012
  3. Williams CD. Chapter: Myopathies. In: Drug Induced Diseases, 2nd Ed. Published by American Society of Health-System Pharmacy. 2010
  4. Williams CD, Haffner S. Primary and Secondary Prevention: Lipid Outcome Studies in Diabetes. In: Therapy for Diabetes Mellitus and related disorders, 5th Ed., American Diabetes Association, Lebovitz HE (ed.), 2009 pp: 598-607.
  5. Williams C. NSAID-induced ulcer disease. In: Schwinghammer TL, Koehler JM, eds. Pharmacotherapy Casebook: A Patient-Focused Approach. 7th ed. New York: McGraw-Hill, 2008.
  6. Williams CD. Controversies in managing cardiovascular disease in patients with chronic kidney disease.  Pharmacotherapy Self Assessment Program (PSAP). April, 2007; 6th Ed. Book 2. 
  1. Schellhase EM, Chen JT, Jordan J, Kania DS, Overholser BR, Shepler BM, Sowinski KM, Williams CD, Pharmacology In: Magee DJ, Zachazewski JE, Quillen WS (eds.). Musculoskeletal Rehabilitation Series, Volume II, Scientific Foundations and Principles of Practice. 2006 2nd Ed. W.B. Saunders, Philadelphia.
  2. Williams CD.  “Progression of renal disease.”  Pharmacotherapy Self Assessment Program (PSAP). 2003; Fourth Ed. Book 9:261-297.

Articles, peer reviewed: 

  1. Ganesan S, Williams CD, Maslan CL, Cherala G. Clopidogrel variability: role of plasma protein binding alterations. British Journal of Clinical Pharmacology. 2013;75:1468-77.
  2. Williams CD. Is microalbuminuria a disease? Pharmacotherapy. 2012;32(9)781-783.
  3. Marriott L, Cameron WE, Purnell JQ, Cetola S, Ito MK, Williams CD, Newcomb KC, Randall JA, Messenger WB, Lipus AC, Shannon J. Let’s Get Healthy! Health awareness through public participation in an education and research exhibit. Progress in Community Health Partnerships: Research, Education and Action. In Press, 2012.
  4. Williams CD, Kirkman MS. Aspirin and other anti-platelet agents and their effects on cardiovascular disease in type 2 diabetes. Curr Cardiovasc Risk Rep. 2012;6:62-70.
  5. Williams CD, Warden B, Willman A. Antithrombotic therapy for secondary prevention of ischemic stroke. Nature Rev Neurology. 2012;8:223-235
  6. Dujovne C, Williams CD, Ito M. What combination treatment with a statin would you recommend? Curr Atheroscler Rep 2011;13:12-22.
  7. Pignone M, Williams CD. Aspirin for primary prevention of cardiovascular disease in diabetes mellitus. Nat Rev Endo 2010;6:619-628.
  8. Pignone M, Alberts MJ, Williams CD, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes. A position statement from ADA, consensus document from ACC and scientific statement from AHA.
    Published simultaneously in:
    Diabetes Care 2010;33:1395-1402
    Circulation 2010;121:
    J Am Coll Cardiol 2010;55:
  9. Williams CD, Marrs JC, Fields SA. Addition of a clinical pharmacist to an inpatient family medicine service. Am J Health-Syst Pharm 2010;67:965-966.
  10. Williams CD, Serebruany V, Cherala G. Application of platelet function testing to the bedside. Thromb Haemo 2010;103:29-33.
  11. Serebruany V, Cherala G, Williams CD, et al. Association of platelet responsiveness with clopidogrel metabolism: role of compliance in the assessment of resistance. Am Heart J 2009;158:925-32.
  12. Williams CD, Tsuyki R. Assessment of muscle pain associated with statins – a tool for pharmacists. C Pharm J 2009;142:280-283.
  13. The American Lung Association Asthma Clinical Research Centers. Efficacy of esomeprazole for treatment of poorly controlled asthma. N Engl J Med 2009;360:1487-99.
  14. Williams CD. Not so choppy SEAS. J Clin Lipidology 2009;3:11-13
  15. Williams CD. Reduction in 10-year risk of major CVD end points (CHD death/nonfatal MI) in major statin trials, or substudies of major trials, in diabetic subjects (n=16,032). Table in Prevention and Management of Diabetes Complications. Diabetes Care 2008;31:S26.
  16. Deeg MA, Raikwar NS, Johson C, Williams CD. Statin therapy reduces serum levels of glycosylphosphatidylinositol-specific phospholipase D. Translational Research 2007;150:153-7 (with editorial).
  17. Antons, K, Williams C, Baker SK, Phillips PS. Clinical perspectives of statin-induced rhabdomyolysis. American Journal of Medicine 2006;119:400-409.
  18. Jacob S, Williams CD, Deeg M. Fenofibrate, simvastatin and rhabdomyolysis. Diabetes Care 2005;28(5):1258
  19. Vasavada N, Williams CD, Hellman R. Ethylene glycol intoxication: case report and pharmacokinetic perspectives. Pharmacotherapy 2003;23(12):1652-58.
  20. Williams CD, “Amlodipine PREVENTS angina, not atherosclerosis.” Pharmacotherapy 2002;22:400-402.
  21. Williams CD, “Potency of inhaled corticosteroid fails to predict reduced Emergency Department visits.” Peer-reviewed research letter Arch Int Med 2003;163:247-249.
  22. Williams CD.  “Costs and outcomes of switching amlodipine to felodipine” AJHP 2000;57:2287-2288.

23.  Williams CD, Wright L.  “Osteoarthritis: update on pathology, pathogenesis and treatment.”  Journal of Pharmacy Practice 1999 12(4):293-307

Functional Group: 

History

Member for
3 years 3 weeks